Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

24.98 -0.02 (-0.08%)
Streaming Delayed Price Updated: 3:56 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,677,773
Open 25.18
Bid (Size) 24.97 (2)
Ask (Size) 24.98 (2)
Prev. Close 25.00
Today's Range 24.13 - 25.40
52wk Range 8.790 - 42.20
Shares Outstanding 41,969,994
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Via Benzinga
Exposures Fossil Fuels

Performance

YTD
+11.42%
+11.42%
1 Month
-7.24%
-7.24%
3 Month
+123.84%
+123.84%
6 Month
+1.92%
+1.92%
1 Year
+29.10%
+29.10%

More News

Read More
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Cassava Sciences Unusual Options Activity
Via Benzinga
Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Market Whales and Their Recent Bets on SAVA Options
Via Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Cassava Sciences Stock Dived by Almost 11% Today
Via The Motley Fool
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cassava Sciences Resolves SEC Investigation
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Stock Rises On Interim Safety Review Of Simufilam Phase 3 Trials
Via Benzinga
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Names Rick Barry as Chief Executive Officer
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Via MarketBeat
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q2 2024
Via InvestorPlace
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences News: Why Is SAVA Stock Trending Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.